Multifocal Motor Neuropathy
12
2
3
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (12)
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)
HyQvia in Multifocal Motor Neuropathy
Effect of Resistance and Aerobic Exercise in CIDP or MMN
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.
Immunoglobulin Dosage and Administration Form in CIDP and MMN
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy